Ibandronate

Ibandronic acid or ibandronate sodium is a potent bisphosphonate drug developed by Hoffman La Roche and used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer.

Ibandronate

Ibandronic Acid; Ibandronate; Bonviva; Bondronat

Bandrone, Bondria, Bondronat, Bonimet, Bonviva, Calinta Kit, Egyban, Idrofos, Idrofos-Kit, Irbez, Monthiba, Osteokit, Vebalone

{1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid

NA

NA

PO: The recommended dose is 2.5 mg once daily or 150 mg once monthly, before food.

For the treatment and prevention of osteoporosis in postmenopausal women.

Back pain, pain in the arms or legs, abdominal pain and diarrhea. Chest pain, upper respiratory infection, inflammation of bronchus and pneumonia. 

• Having any of these for at least 60 minutes after this should be avoided. Ibandronate tablet. Food, mineral water, beverages, antacids, milk or milk products, vitamins and mineral supplements including calcium may interact with Ibandronate tablets.
• This drug may interact with all NSAIDs such as piroxicam, ketoprofen, celecoxib, ibuprofen, naproxen, indomethacin, ketorolac and diclofenac.

Contraindicated to known hypersensitivity, patients with esophagus abnormalities, inability to stand or sit and decreased calcium level in blood.

Store at room temperature

Molecular weight

319.2289

Molecular formula

C9H23NO7P2

CAS number

114084-78-5

Precautions

This drug should not be prescribed for patients with esophageal disorders, severe renal disease, vitamin-D deficiency, dysphagia, hypocalcemia and Ibandronate allergy.